ClinicalTrials.gg
CompletedNCT07331545Updated Sep 2, 2026

Safety, Tolerability, PK, PD, and Immunogenicity of QL2401 in Healthy Chinese Adults

A Phase 1 interventional study of QL2401 and Placebo in Metabolic Dysfunction-Associated Steatohepatitis(MASH), sponsored by Qilu Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
71
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 63 studies in Fatty Liver with a site in China — 30 open to participants now, 34 under way, 2 of them phase 3. Fatty Liver · China.

Enrollment
24th of 37
71 · median 90
Started
2026
with 10 others
Phase 1
6 of 63
3 open now
Registered
52nd of 63
by date

Among the 63 studies in Fatty Liver with a site in China, this one is the 24th largest by enrollment of the 37 interventional ones that give a count, is one of 11 that started in 2026, is one of 6 in phase 1, and was the 52nd registered.

Fatty Liver

664 studies on the registry are indexed under Fatty Liver; 186 are open to participants now.

Browse Fatty Liver studies →

Open to participants now

30 of the 63 studies in Fatty Liver with a site in China are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 117 Fatty Liver studies recruiting now, 35 (30%) set no upper age limit and 63 (54%) stop at 75 or younger; 8 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Fatty Liver with a site in China, or all of them as a file.
02

Study summary

This is a first-in-human, Phase I, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of QL2401 following single and multiple ascending subcutaneous doses in healthy Chinese adults. The study consists of two parts: single ascending dose (SAD) and multiple ascending dose (MAD). Participants will be randomly assigned to receive either QL2401 or placebo. The primary objective is to assess safety and tolerability. Secondary objectives include evaluation of PK parameters in SAD \& MAD; exploratory objectives include assessment of PD biomarkers and immunogenicity.

03

Conditions studied

  • Metabolic Dysfunction-Associated Steatohepatitis(MASH)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male and female participants, aged 18 to 45 years at the time of screening.
  2. Body weight of males should be ≥50.0kg and body weight of females should be≥45.0kg, 18.5-32.5 kg/m² (Including boundary values)at the time of screening.
  3. During the screening and baseline periods, participants with normal laboratory tests, vital sign measurements, physical examination results, 12-lead , and abdominal B-ultrasound results, or those with abnormalities judged by the investigators as having no clinical significance (MAD section: those with lipid indicators and abdominal B-ultrasound results but meeting the following criteria can be included: TC\< 7.2mmol/L, LDL-C\< 4.9mmol/L, TG\< 4.52mmol/L; Abdominal B-ultrasound indicates mild or moderate fatty liver).
  4. Participants voluntarily signed the form before the trial.
  5. Willing to use and comply with study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Serious, progressive, and uncontrolled diseases, including but not limited to the cardiovascular system, endocrine and metabolic system, immune system, urinary system, digestive system, respiratory system, blood system, gynecological system, nervous system, mental system, and musculoskeletal system, and the researcher determines that the participant is not suitable for this trial;
  2. Serious or chronic recurrent gastrointestinal diseases (such as chronic diarrhea, active ulcer, reflux esophagitis), or screening before 12 weeks underwent gastrointestinal surgery;
  3. History of acute or chronic pancreatitis, history of symptomatic gallbladder, pancreas injury can lead to high risk factors of acute pancreatitis, or screening blood amylase > 1.5 x (ULN);
  4. Type 1 diabetes, type 2 diabetes or other types of diabetes;
  5. Abnormal liver, renal, or cardiac function
  6. Positive for , C, , or syphilis
  7. Pregnant or breastfeeding women
  8. History of drug or alcohol abuse
  9. Use of prescription drugs within 2 weeks prior to dosing
  10. According to the researcher's judgment, it may increase the risks related to the research, may interfere with the interpretation of the research results.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    QL2401

    Drug: QL2401

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugQL2401

    QL2401 is a recombinant fusion protein administered via subcutaneous injection. Participants will receive single or multiple ascending doses of QL2401.

  • DrugPlacebo

    Matching placebo administered via subcutaneous injection.

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events

    Safety and tolerability as assessed by the incidence and severity.

    Time frame: From baseline up to 29 days after last dose (SAD) or 57 days after last dose(MAD)

07

Study locations

1 site
  • No. 8888 Lvyou Road
    Jinan, Shandong 250000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2026 to primary completion in Jun 2026, 5 months.

Of 22 phase 1 interventional studies under Fatty Liver, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 29, 2025
First posted
Jan 12, 2026
StartActual
Jan 21, 2026
Primary completionActual
Jun 24, 2026
CompletionActual
Jun 24, 2026
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07331545
Responsible party
Sponsor
First posted
Jan 12, 2026
Start date
Jan 21, 2026
Primary completion
Jun 24, 2026
Completion
Jun 24, 2026
Last update
Sep 2, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion